MPM BIOVENTURES 2018, L.P. sold $462K of TRDA (indirect holdings)
MPM BIOVENTURES 2018, L.P. sold 62,714 indirectly-held shares of Entrada Therapeutics, Inc. (TRDA) at an average of $7.36 ($7.06–$7.54, $0.46M total) across 3 trades over 2026-08-24 to 2026-08-26. Filed jointly with MPM BioVentures 2018 LLC (10% owner) and MPM BioVentures 2018 GP LLC (10% owner).
How this was made
The 30-second read
Why it matters
The disclosed sale reduces a major investor's stake but does not materially alter control or strategic direction.
Market read
A modest insider sale; likely limited price impact but worth noting for short‑term traders.
What to watch
No 10b5‑1 plan was used; the timing may reflect liquidity needs rather than outlook.
Background
Entrada Therapeutics (TRDA) is a clinical‑stage biotech focused on oncology. Insider transactions are publicly reported via Form 4.
Ticker impact
SEC Form 4 disclosed a 62,714‑share open‑market sale by MPM BioVentures, reducing its stake to 4.3M shares.
Minor downward pressure on TRDA price in the short term.
The transaction size (~$462K) is small relative to market cap; insider sales often cause slight price dips but the impact is limited.
Market effects
Biotech sector may see slight sentiment drag as insider sales are monitored.
U.S. biotech investors may adjust positions modestly.
Limited to investors tracking Entrada Therapeutics.
Counterpoint
The sale could be a routine portfolio rebalancing rather than a negative signal.
Key entities
- CompanyEntrada Therapeutics, Inc.
Biopharmaceutical company whose shares were sold.
- InvestorMPM BioVentures 2018, L.P.
Insider reporting a 62,714‑share sale.
